Skip to content

US · CMPX · BIOTECHNOLOGY

Compass Therapeutics, Inc. (CMPX) intrinsic value and stock valuation

$0.69as of 2026-11-21 · Mkt cap 340.37M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Compass Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values CMPX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CMPX’s statements →

Compass Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02135 compasstherapeutics.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-66.49M
20192025
Free cash flow
-$-49.17M
20192025
Total equity
$196.8M+37.6% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$850K$0.00$0.00$0.00
Operating income-$-72.84M-$-56.62M-$-50.36M-$-41.66M-$-81.88M
Net income-$-66.49M-$-49.38M-$-42.49M-$-39.23M-$-82.18M
EPSd-$-421.65K-$-360.15K-$-334.49K-$-372.94K-$-1.31M
Operating cash flow-$-49.14M-$-44.85M-$-40.62M-$-34.12M-$-19.67M
Capital expenditure-$-30K-$-40K-$-30K-$-210K-$-1.57M
Free cash flow-$-49.17M-$-44.9M-$-40.65M-$-34.34M-$-21.23M
Total assets$219.6M$140.4M$156.9M$199.7M$153.8M
Total debt$9.83M$6.63M$1.73M$2.94M$4.04M
Net debt-$-20.81M-$-36.85M-$-22.5M-$-32.01M-$-140.48M
Total equity$196.8M$125.2M$148.5M$181.6M$140.1M
Cash and short-term investments$208.9M$126.7M$152.5M$186.6M$144.5M
Income statement
20252024202320222021
Revenue$0.00$850K$0.00$0.00$0.00
Cost of revenue$1.47M$0.00$0.00$0.00$0.00
Gross profit-$-1.47M$850K$0.00$0.00$0.00
Research and development expenses$56M$42.3M$38.1M$30M$20.3M
Selling, general and administrative expenses$16.9M$15.1M$12.2M$11.7M$10.9M
Other expenses-$-1.47M$0.00$0.00$0.00$50.6M
Operating expenses$71.4M$57.5M$50.4M$41.7M$81.9M
Cost and expenses$72.8M$57.5M$50.4M$41.7M$81.9M
Interest income$6.35M$7.3M$7.9M$2.36M$30K
Interest expense$0.00$0.00$0.00$2.36M$370K
Depreciation and amortization$1.47M$1.75M$1.89M$1.9M$1.62M
Ebitda-$-65.02M-$-47.62M-$-40.6M-$-34.96M-$-80.19M
Operating income-$-72.84M-$-56.62M-$-50.36M-$-41.66M-$-81.88M
Total other income/expenses, net$6.35M$7.25M$7.87M$2.43M-$-300K
Income before tax-$-66.49M-$-49.38M-$-42.49M-$-39.23M-$-82.18M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-66.49M-$-49.38M-$-42.49M-$-39.23M-$-82.18M
Weighted average shares outstanding$157.7M$137.1M$127M$105.2M$62.9M
Weighted average diluted shares outstanding$157.7M$137.1M$127M$105.2M$62.9M
Balance sheet
20252024202320222021
Cash and short-term investments$208.9M$126.7M$152.5M$186.6M$144.5M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$209.8M$132.8M$153.9M$194.8M$147.1M
Property, plant and equipment, net$9.2M$7.08M$2.67M$4.53M$6.33M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$9.77M$7.65M$2.99M$4.85M$6.65M
Total assets$219.6M$140.4M$156.9M$199.7M$153.8M
Accounts payable$1.58M$2.25M$4.09M$3.38M$870K
Short-term debt$1M$340K$1.2M$1.1M$990K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$14M$8.87M$7.8M$16.2M$10.6M
Long-term debt$8.83M$6.3M$540K$1.84M$3.05M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$8.83M$6.3M$540K$1.84M$3.05M
Capital lease obligations$1M$6.63M$1.73M$2.94M$4.04M
Total liabilities$22.8M$15.2M$8.34M$18M$13.7M
Common stock$20K$10K$10K$10K$10K
Retained earnings-$-431.17M-$-364.68M-$-315.31M-$-272.81M-$-233.59M
Accumulated other comprehensive income (loss)$280K$210K$40K-$-300K$0.00
Total equity$196.8M$125.2M$148.5M$181.6M$140.1M
Total investments$178.3M$83.2M$128.2M$151.7M$0.00
Total debt$9.83M$6.63M$1.73M$2.94M$4.04M
Net debt-$-20.81M-$-36.85M-$-22.5M-$-32.01M-$-140.48M
Cash flow statement
20252024202320222021
Net income-$-66.49M-$-49.38M-$-42.49M-$-39.23M-$-82.18M
Depreciation and amortization-$-1.4M$1.75M$1.89M$1.9M$1.62M
Stock-based compensation$8.37M$8.56M$6.12M$5.33M$4.03M
Change in working capital$9.18M-$-4.14M-$-2.91M-$-1.26M$6.25M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-660K-$-1.84M$710K$2.52M-$-190K
Net cash provided by operating activities-$-49.14M-$-44.85M-$-40.62M-$-34.12M-$-19.67M
Investments in property, plant and equipment-$-30K-$-40K-$-30K-$-210K-$-1.57M
Acquisitions, net$0.00$0.00$0.00$180K$120K
Net cash used for investing activities-$-93.31M$46.8M$27M-$-151.2M-$-1.77M
Common stock issued$130.6M$18.1M$3.09M$76.2M$128.3M
Common stock repurchased$0.00$0.00-$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$129.6M$17.3M$2.94M$75.8M$118.6M
Net change in cash-$-12.84M$19.3M-$-10.72M-$-109.57M$97.2M
Cash at end of period$31.2M$43.5M$24.2M$35M$144.5M
Operating cash flow-$-49.14M-$-44.85M-$-40.62M-$-34.12M-$-19.67M
Capital expenditure-$-30K-$-40K-$-30K-$-210K-$-1.57M
Free cash flow-$-49.17M-$-44.9M-$-40.65M-$-34.34M-$-21.23M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Compass Therapeutics, Inc.

        Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.

        CEO
        Thomas J. Schuetz
        Employees
        39
        Beta
        0.75

        Explore

        Frequently asked questions

        What is the intrinsic value of Compass Therapeutics, Inc. (CMPX)?

        InvestorsCraft does not currently publish an intrinsic value for CMPX. How the IC value is calculated.

        Is CMPX undervalued?

        InvestorsCraft does not publish an undervaluation signal for CMPX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.